Ketoconazole potentiates the antitumor effects of nocodazole: In vivo therapy for human tumor xenografts in nude mice

Molecular Carcinogenesis

Volumn 34, Issue 4, 2002, Pages 199-210

  Wang, Ying Jan ^a   Jeng, Jiiang Huei ^b   Chen, Rong Jane ^c   Tseng, How ^c   Chen, Li Ching ^d   Liang, Yu Chih ^c   Lin, Chien Huang ^c   Chen, Chien Ho ^c   Chu, Jan Show ^e   Ho, Wei Lu ^e   Ho, Yuan Soon ^c  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d TZU CHI UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; Ketoconazole; Nocodazole; Nude mice; p27 KIP1

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CYCLIN D3; CYCLIN DEPENDENT KINASE 4; CYTOCHROME C; DNA FRAGMENT; DNA NUCLEOTIDYLEXOTRANSFERASE; KETOCONAZOLE; NOCODAZOLE; PROTEIN BAX; PROTEIN P21; PROTEIN P27;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; ENZYME RELEASE; GENE INDUCTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TOXICITY; TUMOR GROWTH; TUMOR XENOGRAFT; WESTERN BLOTTING;

ADENOCARCINOMA; ANIMALS; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARRIER PROTEINS; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; CYCLINS; CYTOCHROME C GROUP; DRUG SYNERGISM; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KETOCONAZOLE; MICE; MICE, NUDE; NOCODAZOLE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 0036322005     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/mc.10066     Document Type: Article

References (62)

1. Tinea capitis: An overview with emphasis on management
2. Ketoconazole therapy for women with acne and/or hirsutism
3. Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes
4. Effects of ketoconazole on cholesterol synthesis
5. Ketoconazole therapy for advanced prostate cancer
6. Endoerine effects of high-dose ketoconazole therapy in advanced prostatic cancer
7. Ketoconazole and Liarozole in the treatment of advanced prostatic cancer
8. Efficacy of microtubule-active drugs followed by ketoconazole in human metastatic prostate cancer cell lines
9. The treatment of advanced prostate cancer with ketoconazole: Safety issues
10. Cytotoxicity of ketoconazole in malignant cell lines
11. Potentiation of interleukin 1 alpha mediated antitumor effects by ketoconazolse
12. Inhibition of hepatic metastasis from a human pancreatic adenocarcinoma (RWP-2) in the nude mouse by prostacyclin, forskolin, and ketoconazole
13. Ketoconazole: A thromboxane synthetase and 5-lipoxygenase inhibitor with antimetastatic activity in B16-F10 melanoma
14. Ketoconazole induces G0/G1 arrest in human colorectal and hepatocellular carcinoma cell lines
15. Ketoconazole-induced apoptosis through p53-dependent pathway in human colorectal and hepatocellular carcinoma cell lines
16. Regulation of the G1 phase of the mammalian cell cycle
17. Cell cycle control and cancer
18. Cell cycle control
19. Cell cycle regulation by the Cdc25 phosphatase family
20. Protease inhibitor-induced apoptosis: Accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition
21. Ketoconazole therapy in advanced prostatic cancer
22. Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750
23. Tumor and lymphoid cell lines from a patient with carcinoma of the colon for a cytotoxicity model
24. Griseofulvin potentiates antitumorigenesis effects of nocodazole through induction of apoptosis and G2/M cell cycle arrest in human colorectal cancer cells
25. Induction of apoptosis in human tumour xenografts after oral administration of uracil and tegafur to nude mice bearing tumours
26. p53 gene mutational spectra in hepatocellular carcinomas induced by 2-acetylaminofluorene and N-nitroso-2-acetylaminofluorene in rats
27. A novel role for the cyclin-dependent kinase inhibitor p27(Kip1) in angiotensin II-stimulated vascular smooth muscle cell hypertrophy
28. Anti-sense oligonucleotide of p21(waf1/cip1) prevents interleukin 4-mediated elevation of p27(kip1) in low grade astrocytoma cells
29. Potent inhibition of tumor survival in vivo by beta-lapachone plus taxol: Combining drugs imposes different artificial checkpoints
30. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest
31. Control of cell cycle by the p27. Cdk-inhibitor
32. Promoting apoptosis: A novel activity associated with the cyclin-dependent Kinase inhibitor p27
33. Expression of p27 is associated with Bax expression and spontaneous apoptosis in oral and oropharyngeal carcinoma
34. Treatment of systemic mycoses with ketoconazole: Emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study
35. Ketoconazole. Mechanism of action, spectrum of activity, pharmacokinetics, drug interactions, adverse reactions and therapeutic use
36. Clinical pharmacokinetics of ketoconazole
37. TNF-alpha induced p21(WAF1) but not Bax in colon cancer cells WiDr with mutated p53: Important role of protein stabilization
38. Quercetin inhibits p21-RAS expression in human colon cancer cell lines and in primary colorectal tumors
39. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells
40. Molecular markers in chemoprevention of colon cancer. Inhibition of expression of ras-p21 and p53 by sulindac during azoxymethane-induced colon carcinogenesis
41. Reduced expression and altered subcellular localization of the cyclin-dependent kinase inhibitor p27(Kip1) in human colon cancer
42. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis
43. WAF1, a potential mediator of p53 tumor suppression
44. p27 modulates cell cycle progression and chemosensitivity in human malignant glioma
45. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis
46. p53 in signaling checkpoint arrest on apoptosis
47. p53 derived from human tumour cell lines and containing distinct point mutations can be activated to bind its consensus target sequence
48. Mutation spanning P53 exons 5-9 detected by non-isotopic RNAse cleavage assay and protein expression in human colon cancer
49. Colon cancer: p53 expression and DNA ploidy. Their relation to proximal or distal tumor site
50. A comparative study on p53 gene mutation in primary human Dukes C colon cancer with that in matched lymph node metastasis
51. p53 functional loss in a colon cancer cell line with two missense mutations (218leu and 248trp) on separate alleles
52. Colon cancer and the p53 oncogene
53. p53 gene mutation, microsatellite instability and adjuvant chemotherapy: Impact on survival of 388 patients with Dukes C colon carcinoma
54. The role of p53 in gemcitabine-mediated cytotoxicity and radiosensitization
55. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: A Southwest Oncology Group study
56. New directions in the treatment of colorectal cancer: A look to the future
57. Efforts to combine endocrine and chemotherapy in the management of breast cancer: Do two and two equal three?
58. Why and how to combine chemotherapy and radiation therapy in breast cancer patients
59. Beta-lapachone induces cell cycle arrest and apoptosis in human colon cancer cells
60. A link between cell cycle and cell death: Bax and Bcl-2 modulate Cdk2 activation during thymocyte apoptosis
61. Overexpression of retinoic acid receptor beta induces growth arrest and apoptosis in oral cancer cell line
62. Modulation of apoptosis by the cyclin-dependent kinase inhibitor p27(Kip1)